Showing results (51-60 of 71) with videos related to
Sort By:
Pageof 8
Blood Advances|September 1, 2023
Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomesSheila K Pierson, Megan S Lim, Gordan Srkalovic, et al.British Journal of Haematology|August 8, 2015
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphomaJonathon B Cohen, Jeffrey M Switchenko, Jean L Koff, et al.Transfusion|June 10, 2010
Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host diseaseMojtaba Akhtari, Cynthia R Giver, Zahir Ali, et al.Leukemia & Lymphoma|July 18, 2012
Examining racial differences in diffuse large B-cell lymphoma presentation and survivalChristopher R Flowers, Pareen J Shenoy, Uma Borate, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL studyOwen A O'Connor, Barbara Pro, Lauren Pinter-Brown, et al.American Journal of Hematology|September 7, 2020
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, David Wu, Aaron Goodman, et al.Journal of the American Academy of Dermatology|October 1, 2025
Racial differences in mycosis fungoides and Sézary syndrome: A multicenter cohort studyPamela B Allen, Subir Goyal, Swaminathan Iyer, et al.The Lancet. Haematology|December 4, 2018
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 studyKieron Dunleavy, Michelle A Fanale, Jeremy S Abramson, et al.Acta Haematologica|July 18, 2019
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE RegistryFrederick Lansigan, Steven M Horwitz, Lauren C Pinter-Brown, et al.Blood Advances|February 14, 2025
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registrySheila K Pierson, Joshua D Brandstadter, Drew A Torigian, et al.Pageof 8